An observational study in Acute Ischemic Stroke, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-24.
Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 164 studies in Ischemic Stroke with a site in Germany — 41 open to participants now, 50 under way, 5 of them phase 3. Ischemic Stroke · Germany.
Among the 164 studies in Ischemic Stroke with a site in Germany, this one is the 27th largest by planned enrollment of the 61 observational ones that give a count, is one of 13 that started in 2023, is one of 61 observational ones, reaches primary completion later than 22 of the 49 other live ones, and was the 111th registered.
2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.
Browse Ischemic Stroke studies →41 of the 164 studies in Ischemic Stroke with a site in Germany are open now. Recruiting first, the newest first:
Ludwig-Maximilians - University of Munich · Sites in Germany
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Germany, Belgium, Italy and 3 more countries
Ages 18+
Charite University, Berlin, Germany · Sites in Germany
Giuseppe Tarantini · Sites in Germany
Ages 18–65
Takeda · Sites in Germany, United States, Belgium and 7 more countries
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
164 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 33 · Phase 3 22 · Phase 4 4
First in 2000; this study’s year is marked. 13 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 300 across 776 observational studies indexed under Ischemic Stroke.
Median enrollment 223 across the 101 interventional studies, 410 across the 61 observational. Of the 98 that completed or were terminated, 25 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 164 have an industry lead sponsor. The 10 most frequent:
Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 416 studies on the registry; 86 are open to participants now.
Universitätsklinikum Hamburg-Eppendorf has 8 studies filed under Ischemic Stroke — fewer than ten, so there is no comparison to draw.
14 of the studies in Ischemic Stroke with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05691244Phase 3Pharmazz, Inc.Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke | 2027-09 |
| NCT07357285iVascular S.L.U.Safety and Efficacy Evaluation of the iNstroke 4F Thromboaspiration Catheter in Patients With Acute Ischaemic Stroke Due to Primary Distal Medium Vessel Occlusions (DMVO) | 2026-11 |
| NCT06121336Ludwig-Maximilians - University of MunichPRecisiOn Medicine In StrokE: Evolution of Plasma Brain-Derived Tau in Acute Stroke | 2026-12-31 |
| NCT07299994Sigmund Freud PrivatUniversitatEfficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease | 2026-12-31 |
| NCT04412187Martin DichgansInflammatory faCtors AfteR acUte Ischemic Stroke | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 164 studies in Ischemic Stroke with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Improving Low ASPECTS Stroke Thromectomy (I-LAST) is an academic, independent, prospective, multicenter, observational registry study. Consecutive patients treated with endovascular stroke treatment will be enrolled in German stroke centers. Patients receive regular care and data will be collected as part of clinical routine. Baseline clinical and procedural information as well clinical follow-up information during in-hospital stay, and up to 90 days of stroke onset are collected. Data collected include demographics, National Institute of Health Stroke Scale (NIHSS) on admission, pre-treatment ASPECTS, information on timing and success of interventional treatment, procedural complications, intracranial hemorrhage, and functional outcome. Advanced imaging biomarkers will be tested and validated aiming to improve treatment selection and outcome prediction of patients presenting with extensive baseline infarction.
This study aims to investigate the role of advanced imaging biomarkers in patients with large early infarct, in particular quantitative lesion water uptake (Minnerup et al. Annals of Neurology 2016), arterial and venous collateral circulation (Faizy et al. Radiology 2021), and multivariate CTP-derived parameters (Kemmling et al. JCBFM 2015). The goal is to use these imaging biomarkers as specific selection criterion to predict clinical benefit after reperfusion despite extensive baseline infarct lesions, also as a method of monitoring adjuvant neuroprotective agents after reperfusion therapy (for instance anti-edematous medication).
All acute stroke patients with the clinical diagnosis of acute ischemic stroke with a ASPECTS 0f 0-5 on baseline imaging; Age >18 years
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
none
acute stroke patients treated with endovascular treatment combined with thrombolysis or without previous thrombolysis Intervention.
Other: Telephone call on day 90 · Diagnostic Test: Quantification of lesion water uptake by CT densitometry
acute stroke patients treated with or without thrombolysis
Other: Telephone call on day 90 · Diagnostic Test: Quantification of lesion water uptake by CT densitometry
telephone call on day 90 to assess the primary outcome (mRs 90)
Retrospective quantification of lesion water uptake by CT densitometry in admission and follow-up imaging
modified ranking scale on day (mRs) day 90
mRs: modified ranking scale; the scale is a commonly used measurement for the degree of disability or dependence in the daily activities of people who have suffered a stroke; scale range 0-6, with 0 - No symptoms. 1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. publication: van Swieten J, Koudstaal P, Visser M, Schouten H, et al. (1988). "Interobserver agreement for the assessment of handicap in stroke patients". Stroke. 19 (5): 604-607. doi:10.1161/01.str.19.5.604.
Time frame: 90 days
Ischemic lesion water uptake on admission
Ischemic lesion water uptake is a CT based quantitative imaging biomarker to assess ischemic edema based on densitometry
Time frame: 0-24 hours after symptom onset
Ischemic lesion water uptake on follow-up imaging
Ischemic lesion water uptake is a CT based quantitative imaging biomarker to assess ischemic edema based on densitometry
Time frame: 24-48 hours after admission
Plan to share: Undecided — Data will be shared upon reasonable request.
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Jan 2027, 44 months after the start.
Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 44 months is below that.
Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitätsklinikum Hamburg-Eppendorf →